Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders

Patent metadata

Field	Value
Publication number	US-12036205-B2
Application number	US-202217576502-A
Country	US
Kind code	B2
Filing date	Jan 14, 2022
Priority date	Dec 23, 2010
Publication date	Jul 16, 2024
Grant date	Jul 16, 2024

Abstract

Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.

First claim

We claim:

1. A method of improving physical endurance; inhibiting or retarding physical fatigue; enhancing energy; reducing muscle fatigue; enhancing cardiac and cardiovascular function; increasing muscle ATP levels; reducing lactic acid in blood; or maintaining, supporting, or improving blood circulation, heart function, or heart muscle function; comprising administering to a human in need thereof an effective amount of a urolithin.

2. The method of claim 1 , wherein physical endurance is improved.

3. The method of claim 1 , wherein physical fatigue is inhibited or retarded.

4. The method of claim 1 , wherein energy is enhanced.

5. The method of claim 1 , wherein muscle fatigue is reduced.

6. The method of claim 1 , wherein stress is reduced.

7. The method of claim 1 , wherein cardiac and cardiovascular function is enhanced.

8. The method of claim 1 , wherein muscle ATP levels are increased.

9. The method of claim 1 , wherein lactic acid in blood is reduced.

10. The method of claim 1 , wherein blood circulation is maintained, supported, or improved.

11. The method of claim 1 , wherein heart function is maintained, supported, or improved.

12. The method of claim 1 , wherein heart muscle function is maintained, supported, or improved.

13. The method of claim 1 , wherein the urolithin is urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof.

14. The method of claim 13 , wherein the urolithin is urolithin A.

15. The method of claim 1 , wherein the urolithin is administered orally.

16. The method of claim 1 , wherein the urolithin is administered parenterally.

17. The method of claim 1 , wherein the urolithin is administered topically.

18. The method of claim 1 , wherein the urolithin is administered as a pharmaceutical composition, a medical food, a functional food, a food additive, a dietary supplement, a food product, or a nutritional supplement; and the urolithin is urolithin A.

19. The method of claim 1 , wherein the urolithin is administered as a medical food, a functional food, a food additive, a dietary supplement, a food product, or a nutritional supplement; and the urolithin is urolithin A.

20. The method of claim 15 , wherein the urolithin is urolithin A.

21. The method of claim 17 , wherein the urolithin is urolithin A.

Assignees

• Amazentis Sa

Inventors

• Rinsch Christopher L
• Blanco-Bose William
• Schneider Bernard
• Thomas Charles
• Sandi Carmen
• Auwerx Johan
• Andreux Penelope
• Houtkooper Richardus
• Pirinen Eija
• Mouchiroud Laurent
• Genoux David

Classifications

• A61K36/185

  Magnoliopsida (dicotyledons) · CPC title

• A23V2200/326

  having effect on cardiovascular health · CPC title

• A23L33/105 Primary

  Plant extracts, their artificial duplicates or their derivatives · CPC title

• A61K31/352

  condensed with carbocyclic rings, e.g. methantheline  {(cannabinoids A61K31/658)} · CPC title

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title